Coya Therapeutics’ (COYA) Buy Rating Reiterated at Roth Capital

Roth Capital reaffirmed their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report sent to investors on Monday,Benzinga reports. They currently have a $12.00 price target on the stock.

Several other equities research analysts have also commented on the stock. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research report on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a report on Friday, July 17th. Chardan Capital reiterated a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $15.33.

Coya Therapeutics Trading Down 3.4%

Shares of COYA stock opened at $4.87 on Monday. The stock has a 50 day simple moving average of $4.90 and a 200-day simple moving average of $4.68. The company has a market cap of $114.25 million, a price-to-earnings ratio of -4.55 and a beta of 0.60. Coya Therapeutics has a 12-month low of $3.71 and a 12-month high of $7.75.

Coya Therapeutics (NASDAQ:COYA) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%.The firm had revenue of $0.24 million for the quarter, compared to the consensus estimate of $0.13 million. On average, equities analysts forecast that Coya Therapeutics will post -1.34 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Prosperity Wealth Management Inc. grew its position in shares of Coya Therapeutics by 16.4% in the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock valued at $136,000 after purchasing an additional 3,350 shares during the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Coya Therapeutics during the 3rd quarter worth approximately $28,000. Cetera Investment Advisers lifted its stake in Coya Therapeutics by 36.4% in the 1st quarter. Cetera Investment Advisers now owns 30,000 shares of the company’s stock valued at $118,000 after buying an additional 8,000 shares in the last quarter. CIBC Private Wealth Group LLC purchased a new stake in Coya Therapeutics in the 4th quarter valued at approximately $47,000. Finally, Occudo Quantitative Strategies LP acquired a new stake in Coya Therapeutics during the 4th quarter valued at $66,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Key Coya Therapeutics News

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and raised its FY2026 EPS estimate to a loss of $1.30 from a prior loss estimate of $1.52. The firm also modestly improved its FY2027 forecast to a $1.64 loss from $1.66, suggesting somewhat better expected cost or operating performance. HC Wainwright estimates
• Positive Sentiment: Analyst coverage remains constructive: Roth Capital assigned COYA a Buy rating, while analysts collectively list an average price target of $15.33—well above the recent trading level. These ratings may support investor confidence in Coya’s longer-term pipeline potential. Coya Therapeutics Earns Buy Rating from Roth Capital Coya Therapeutics Average Analyst Target Price
• Neutral Sentiment: Reported short interest was zero shares as of August 25, unchanged from the prior report. This indicates no measurable short-selling pressure, although the figure provides little incremental trading insight. Coya Therapeutics short interest
• Negative Sentiment: HC Wainwright lowered its Q2 2027 EPS forecast to a $0.48 loss from $0.46 and its Q3 2027 forecast to a $0.40 loss from $0.39. Coya is still expected to remain unprofitable, with consensus calling for a $1.44 per-share loss in the current year and negative margins, which can weigh on the stock despite favorable ratings.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.